Topoi

, Volume 33, Issue 2, pp 339–360 | Cite as

Mechanisms and the Evidence Hierarchy

  • Brendan Clarke
  • Donald Gillies
  • Phyllis Illari
  • Federica Russo
  • Jon Williamson
Article

Abstract

Evidence-based medicine (EBM) makes use of explicit procedures for grading evidence for causal claims. Normally, these procedures categorise evidence of correlation produced by statistical trials as better evidence for a causal claim than evidence of mechanisms produced by other methods. We argue, in contrast, that evidence of mechanisms needs to be viewed as complementary to, rather than inferior to, evidence of correlation. In this paper we first set out the case for treating evidence of mechanisms alongside evidence of correlation in explicit protocols for evaluating evidence. Next we provide case studies which exemplify the ways in which evidence of mechanisms complements evidence of correlation in practice. Finally, we put forward some general considerations as to how the two sorts of evidence can be more closely integrated by EBM.

Keywords

Mechanism Difference-making Evidence Evidence of mechanism Evidence in medicine Evidence-based medicine 

Notes

Acknowledgments

We thank the UK Arts and Humanities Research Council for supporting this research. F. Russo also acknowledges financial support from the FWO-Flanders (2012–2013) as Pegasus Marie Curie Fellow. We are extremely grateful to the very many people who came to various events we organised during 2012, and participated in the discussions that allowed us to develop these ideas. We owe particular thanks to Ian McKay, Barbara Osimani, Jacob Stegenga and David Teira for extensive comments leading to significant improvements to the paper.

References

  1. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN et al (2010) Stopping randomized trials early for benefit and estimation of treatment effects. J Am Med Assoc 303(12):1180–1187CrossRefGoogle Scholar
  2. Bechtel W (2008) Mental mechanisms: philosophical perspectives on cognitive neuroscience. Routledge, OxfordGoogle Scholar
  3. Bell G (2008) Selection: the mechanism of evolution, 2nd edn. OUPGoogle Scholar
  4. Bem DJ (2011) Feeling the future: experimental evidence for anomalous retroactive influences on cognition and affect. J Pers Soc Psychol 100:407–425CrossRefGoogle Scholar
  5. Bernard C (1856) An introduction to the study of experimental medicine. Macmillan, New York (1927 edition)Google Scholar
  6. Bradford Hill A (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300Google Scholar
  7. Bradford Hill A (1990) Memories of the British streptomycin trial. Controlled Clin Trials 2:77–79CrossRefGoogle Scholar
  8. Broadbent A (2011) Inferring causation in epidemiology: mechanisms, black boxes, and contrasts. In: Illari P, Russo F, Williamson J (eds) Causality in the sciences. Oxford University Press, Oxford, pp 45–69CrossRefGoogle Scholar
  9. Brock TD (1988) Robert Koch: a life in medicine and bacteriology, 2 edn. ASM PressGoogle Scholar
  10. Campaner R (2011) Understanding mechanisms in the health sciences. Theor Med Bioethics 32:5–17CrossRefGoogle Scholar
  11. Campaner R, Galavotti MC (2012) Evidence and the assessment of causal relations in the health sciences. Int Stud Philos Sci 26(1):27–45CrossRefGoogle Scholar
  12. Carter KC (2012) The decline of therapeutic bloodletting and the collapse of traditional medicine. Transaction Publishers, New BrunswickGoogle Scholar
  13. Cartwright N (2007) Causal powers: what are they? why do we need them? what can be done with them and what cannot? LSE discussion paper. http://www.lse.ac.uk/CPNSS/projects/CoreResearchProjects/ContingencyDissentInScience/DP/CausalPowersMonographCartwrightPrint%20Numbers%20Corrected.pdf
  14. Cartwright N (2010) What are randomised controlled trials good for? Philos Stud 147:59–70CrossRefGoogle Scholar
  15. Cartwright N, Hardie J (2012) Evidence based policy: a practical guide to doing it better. OUP, USAGoogle Scholar
  16. Cartwright N, Munro E (2010) The limitations of randomized controlled trials in predicting effectiveness. J Eval Clin Pract 16:260–266CrossRefGoogle Scholar
  17. Clarke B (2011a) Causality in medicine with particular reference to the viral causation of cancers. PhD thesis. Department of Science and Technology Studies, University College London, LondonGoogle Scholar
  18. Clarke B (2011b) Causation and melanoma classification. Theor Med Bioethics 32:19–32CrossRefGoogle Scholar
  19. Clarke B, Gillies D, Illari P, Russo F, Williamson J (2013) The evidence that evidence-based medicine omits. Prev Med. doi:10.1016/j.ypmed.2012.10.020
  20. Claveau F (2012) The Russo–Williamson theses in the social sciences: causal inference drawing on two types of evidence. Stud Hist Philos Biol Biomed Sci 43(4):806–813Google Scholar
  21. Cook T, Campbell D (1979) Quasi-experimentation: design and analysis issues for field settings. Rand MacNally, ChicagoGoogle Scholar
  22. Craver C (2007) Explaining the brain. Clarendon Press, OxfordCrossRefGoogle Scholar
  23. Cucherat M, Haugh MC, Gooch M, Boissel J-P (2000) Evidence of clinical efficacy of homeopathy: a meta-analysis of clinical trials. Eur J Clin Pharmacol 56:27–33CrossRefGoogle Scholar
  24. Daniels M, Bradford Hill A (1952) Chemotherapy of pulmonary tuberculosis in young adults. An analysis of the combined results of three medical research council trials. Br Med J 1162–1168Google Scholar
  25. Darby G, Williamson J (2011) Imaging technology and the philosophy of causality. Philos Technol 24(2):115–136CrossRefGoogle Scholar
  26. Darden L (2006) Reasoning in biological discoveries. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  27. Debré P (1994) Louis Pasteur. The John Hopkins University Press. English translation by Elborg Forster, 1998Google Scholar
  28. Demeulenaere P (ed) (2011) Analytical sociology and social mechanisms. Cambridge University Press, CambridgeGoogle Scholar
  29. Dragulinescu S (2012) On ‘stabilising’ medical mechanisms, truth-makers and epistemic causality: a critique to Williamson and Russo’s approach. Synthese 187(2):785–800Google Scholar
  30. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne CM, Stein EA, Tardif J-C, Rudd JHF, Farkouh ME, Tawakol A (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378(9802):1547–1559CrossRefGoogle Scholar
  31. Florey ME (1961) The clinical application of antibiotics. Streptomycin and other antibiotics active Against tuberculosis. vol 2, Oxford University Press, LondonGoogle Scholar
  32. Fox W, Ellard G, Mitchison D (1999) Studies on the treatment of tuberculosis undertaken by the british medical research council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3(10s2):S231–S279Google Scholar
  33. Gillies DA (2011) The Russo–Williamson thesis and the question of whether smoking causes heart disease. In: Illari PM, Russo F, Williamson J (eds) Causality in the sciences, Oxford University Press, Oxford, pp 110–125CrossRefGoogle Scholar
  34. Hedström P, Swedberg R (1988) Social mechanism: an analytical approach to social theory. Cambridge University Press, CambridgeGoogle Scholar
  35. Hitchcock C (2001) A tale of two effects. Philos Rev 110(3):361–396CrossRefGoogle Scholar
  36. Howick J (2011) Exposing the vanities—and a qualified defence—of mechanistic evidence in clinical decision-making. Philos Sci 78(5):926–940. Proceedings of the Biennial PSA 2010Google Scholar
  37. IARC (2006) IARC monographs on the evaluation of carcinogenic risks to humans: preamble. Int Agency Res Cancer, http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf
  38. Illari PM (2011) Mechanistic evidence: disambiguating the Russo–Williamson thesis. Int Stud Philos Sci 25:139–157CrossRefGoogle Scholar
  39. Illari PM, Williamson J (2012) What is a mechanism? thinking about mechanisms across the sciences. Eur J Philos Sci 2:119–135CrossRefGoogle Scholar
  40. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE (2006) Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 119(2):133–141CrossRefGoogle Scholar
  41. La Caze A (2008) Evidence-based medicine can’t be …. Soc Epistemol 22(4):353–370CrossRefGoogle Scholar
  42. La Caze A (2009) Evidence-based medicine must be …. J Med Philos 34:509–527CrossRefGoogle Scholar
  43. La Caze A (2011) The role of basic science in evidence-based medicine. Biol Philos 26(1):81–98CrossRefGoogle Scholar
  44. La Caze A, Djulbegovic B, Senn S (2012) What does randomisation achieve?. Evid Med 17:1–2CrossRefGoogle Scholar
  45. Leibovici L (2001) Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial. Br Med J 323:1450–1451CrossRefGoogle Scholar
  46. Lucas R (1976) Econometric policy evaluation. In: Brunner K, Meltzer A (eds) The Phillips curve and labor markets, volume 1 of Carnegie–Rochester conference series on public policy. North-Holland, Amsterdam, pp 161–168Google Scholar
  47. Machamer P, Darden L, Craver C (2000) Thinking about mechanisms. Philos Sci 67:1–25CrossRefGoogle Scholar
  48. McLaren L, Ghali LM, Lorenzetti D, Rockl M (2006) Out of context? Translating evidence from the North Karelia project over place and time. Health Educ Res 22(3):414–424CrossRefGoogle Scholar
  49. MRC (1948) Streptomycin treatment of pulmonary tuberculosis. Br Med J 769–782Google Scholar
  50. MRC (1949) Treatment of pulmonary tuberculosis with para-aminosalicylic acid and streptomycin: preliminary report. Br Med J 1521Google Scholar
  51. MRC (1950) Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. Br Med J 1073–1085Google Scholar
  52. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J (2007) Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 4(7):e238CrossRefGoogle Scholar
  53. NICE (2006) The guidelines manual. National Institute for Health and Clinical Excellence, London. Available from: http://www.nice.org.uk
  54. NICE (2009) The guidelines manual. National Institute for Health and Clinical Excellence, London. Available from: http://www.nice.org.uk
  55. NICE (2011a) CG117: tuberculosis. National Institute for Health and Clinical Excellence, London. Available from: http://www.nice.org.uk
  56. NICE (2011b) CG127: hypertension: full guideline. National Institute for Health and Clinical Excellence, London. Available from: http://www.nice.org.uk
  57. NICE (2011c) CG127: hypertension: quick reference guide. National Institute for Health and Clinical Excellence, London. Available from: http://www.nice.org.uk
  58. Northcott R (2012) How necessary are randomized controlled trials? In: Munson R (ed) Intervention and reflection: basic issues in medical ethics, 9th edn. Thomson Wadsworth, pp 187–191Google Scholar
  59. OCEBM Levels of Evidence Working Group (2011) The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine, http://www.cebm.net/index.aspx?o=5653
  60. Papineau D (1994) The virtues of randomization. Br J Philos Sci 45:437–450CrossRefGoogle Scholar
  61. Puska P, Vartiaine E, Laatikainen T, Jousilahti P, Paavola M (eds) (2009) The North Karelia Project: from North Karelia to national action. National Institute for Health and WelfareGoogle Scholar
  62. Reichenbach H (1949) The theory of probability: an inquiry into the logical and mathematical foundations of the calculus of probability. University of California Press, Berkeley, CAGoogle Scholar
  63. Rothman K, Greenland S, Lash T (2008) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia, PAGoogle Scholar
  64. Russo F, Williamson J (2007) Interpreting causality in the health sciences. Int Stud Philos Sci 21(2):157–170CrossRefGoogle Scholar
  65. Russo F, Williamson J (2011a) Epistemic causality and evidence-based medicine. History Philos Life Sci 33(4):563–582Google Scholar
  66. Russo F, Williamson J (2011b) Generic versus single-case causality: the case of autopsy. Eur J Philos Sci 1(1):47–69CrossRefGoogle Scholar
  67. Russo F, Williamson J (2012) EnviroGenomarkers: the interplay between mechanisms and difference making in establishing causal claims. Med Stud 3(4):249–262CrossRefGoogle Scholar
  68. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. Br Med J 312(7023):71–72CrossRefGoogle Scholar
  69. Salmon WC (1977) Objectively homogeneous reference classes. Synthese 36(4):399–414CrossRefGoogle Scholar
  70. Salmon WC, Jeffrey RC, Greeno JG (1971) Statistical explanation and statistical relevance. University of Pittsburgh Press, Pittsburgh, PAGoogle Scholar
  71. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367(22):2089–2099. PMID: 23126252Google Scholar
  72. Sober E (1988) The principle of the common cause. In: Fetzer JH (ed) Probability and causality: essays in honour of Wesley C. Salmon. Reidel, Dordrecht, pp 211–228Google Scholar
  73. Solomon M (2011) Just a paradigm: evidence-based medicine in epistemological context. Eur J Philos Sci 1:451–466CrossRefGoogle Scholar
  74. Steel D (2008) Across the boundaries: extrapolation in biology and social science. Oxford University Press, OxfordGoogle Scholar
  75. Stegenga J (2011) Is meta-analysis the platinum standard of evidence. Stud History Philos Biol Biomed Sci 42:497–507CrossRefGoogle Scholar
  76. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG (2010) Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 31(4):480–488CrossRefGoogle Scholar
  77. Thompson RP (2011) Causality, theories and medicine. In: Illari PM, Russo F, Williamson J (eds) Causality in the sciences. Oxford University Press, Oxford, pp 25–44CrossRefGoogle Scholar
  78. Timmermans S, Berg M (2003) The gold standard: the challenge of evidence-based medicine and standardization in health care. Temple University Press, PhiladelphiaGoogle Scholar
  79. Victora CG, Habicht J-P, Bryce J (2004) Evidence-based public health: moving beyond randomized trials. Am J Public Health 94:400–405CrossRefGoogle Scholar
  80. Wagner EH (1982) The North Karelia Project: what it tells us about the prevention of cardiovascular disease. Am J Public Health 72(1):51–53CrossRefGoogle Scholar
  81. Weber E (2009) How probabilistic causation can account for the use of mechanistic evidence. Int Stud Philos Sci 23(3):277–295CrossRefGoogle Scholar
  82. Williamson J (2005) Bayesian nets and causality: philosophical and computational foundations. Oxford University Press, OxfordGoogle Scholar
  83. Williamson J (2013) How can causal explanations explain? Erkenntnis. doi:10.1007/s10670-013-9512-x
  84. Worrall J (2002) What evidence in evidence-based medicine. Philos Sci 69:S316–S330CrossRefGoogle Scholar
  85. Worrall J (2007) Why there’s no cause to randomize. Br J Philos Sci 58:451–488CrossRefGoogle Scholar
  86. Worrall J (2010) Evidence: philosophy of science meets medicine. J Eval Clin Pract 16:356–362CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Brendan Clarke
    • 1
  • Donald Gillies
    • 1
  • Phyllis Illari
    • 1
  • Federica Russo
    • 2
  • Jon Williamson
    • 3
  1. 1.Science and Technology StudiesUniversity College LondonLondonUK
  2. 2.Dipartimento di Studi UmanisticiUniversità degli Studi di FerraraFerraraItaly
  3. 3.Philosophy, SECLUniversity of KentCanterburyUK

Personalised recommendations